Scanadu has secured $35 million in Series B funding bringing its total funding to date to $49.7 million. Fosun International and Tencent Holdings Limited led the round, with participation from China Broadband Capital and Iglobe Partners of Singapore, as well as A-round investors Relay Ventures, Redmile Group, Ame Cloud Ventures and Three Leaf Ventures, an affiliate of The Broe Group.
Scanadu has raised $49.7 million to date.“We continue to build out our family of products and move down the path to regulatory clearance in the U.S. and China,” said Scanadu founder and CEO Walter De Brouwer. “Scanadu’s mission has always been to give eight billion people access to quality healthcare via their smartphones.”
The company has also announced the recent expansion of its Board of Directors. New appointees include Dr. Robert Harrington, MD – Arthur L. Bloomfield Professor of Medicine and Chair of the Department of Medicine at Stanford University; and Ezra Kucharz – President of Local Digital Media at CBS Corporation.
This month Scanadu will complete shipment of their first set of investigational Scanadu Scout devices to their more than 8,000 Indiegogo supporters. Said device can measures heart rate, core body temperature, blood oxygenation, and cuffless and calibration-free systolic and diastolic blood pressure in one scan in seconds, and shares those results to an iOS or Android app. Scanadu is currently working toward FDA submission and approval for that device, as well as Scanadu Urine (formerly known as ScanaFlo), an at-home urine test that similarly shares important health data to your smartphone.